The prognostic role of circulating tumor cells in heavily pretreated individuals with a low life expectancy

Future Oncology

Volumn 10, Issue 16, 2014, Pages 2555-2560

  Stebbing, Justin ^a,b   Harding, Victoria ^a   Urch, Catherine E ^a   Kaier, Thomas ^a   Schofield, Guy ^a   Flook, Matthew ^a   Alifrangis, Constantine ^a   Young, Anna Mary ^a   Shaw, Jacqueline A ^a   Coombes, R Charles ^a   Krell, Jonathan ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

biomarker; cancer; circulating tumor cell; cut off >100; hospice; life expectancy; overall survival; palliative

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

ADULT; AGED; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; DYING; EXTERNAL VALIDITY; FAMILY; FEMALE; HAZARD RATIO; HUMAN; LIFE EXPECTANCY; METASTASIS; OVERALL SURVIVAL; QUALITY OF LIFE; REVIEW; TERMINAL CARE; BLOOD; BREAST NEOPLASMS; CELL COUNT; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR EMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL COUNT; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIFE EXPECTANCY; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS;

EID: 84919786122     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.107     Document Type: Review

References (24)

1. Hagerty RG, Butow PN, Ellis PA et al. Cancer patient preferences for communication of prognosis in the metastatic setting. J. Clin. Oncol. 22(9), 1721-1730 (2004).
2. Kiely BE, Tattersall MH, Stockler MR. Certain death in uncertain time: Informing hope by quantifying a best case scenario. J. Clin. Oncol. 28(16), 2802-2804 (2010).
3. Hagerty RG, Butow PN, Ellis PM et al. Communicating with realism and hope: Incurable cancer patients' views on the disclosure of prognosis. J. Clin. Oncol. 23(6), 1278-1288 (2005).
4. Gould SJ. The median is not the message. Discover 6, 40-42 (1985).
5. Davey HM, Butow PN, Armstrong BK. Cancer patients' preferences for written prognostic information provided outside the clinical context. Br. J. Cancer 89(8), 1450-1456 (2003).
6. Lobb EA, Butow PN, Kenny DT, Tattersall MH. Communicating prognosis in early breast cancer: Do women understand the language used? Med. J. Aust. 171(6), 290-294 (1999).
7. Francis PA. Surprised by hope. J. Clin. Oncol. 26(36), 6001-6002 (2008).
8. Stebbing J, Jiao LR. Circulating tumour cells as more than prognostic markers. Lancet Oncol. 10(12), 1138-1139 (2009).
9. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351(8), 781-791 (2004).
10. Cristofanilli M, Hayes DF, Budd GT et al. Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 23(7), 1420-1430 (2005).
11. Budd GT, Cristofanilli M, Ellis MJ et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 12(21), 6403-6409 (2006).
12. Giordano A, Egleston BL, Hajage D et al. Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients. Clin. Cancer Res. 19(6), 1596-1602 (2013).
13. Krell J, Stebbing J. Circulating tumour cells as biomarkers in early breast cancer. Lancet Oncol. 13(7), 653-654 (2012).
14. Lucci A, Hall CS, Lodhi AK et al. Circulating tumour cells in non-metastatic breast cancer: A prospective study. Lancet Oncol. 13(7), 688-695 (2012).
15. Franken B, de Groot MR, Mastboom WJ et al. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res. 14(5), R133 (2012).
16. Bidard FC, Belin L, Delaloge S et al. Time-dependent prognostic impact of circulating tumor cells detection in non-metastatic breast cancer: 70-month analysis of the REMAGUS02 study. Int. J. Breast Cancer 2013, 130470 (2013).
17. Jiao LR, Apostolopoulos C, Jacob J et al. Unique localization of circulating tumor cells in patients with hepatic metastases. J. Clin. Oncol. 27(36), 6160-6165 (2009).
18. Payne RE, Yague E, Slade MJ et al. Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics 10(1), 51-57 (2009).
19. Pestrin M, Bessi S, Puglisi F et al. Final results of a multicenter Phase II clinical trial evaluating the activity of single-Agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res. Treat.134(1), 283-289 (2012).
20. Graham ML, Fleming N, Pinto A, Dropkin E. Circulating tumor cells (CTCs) and association with survival in molecular subtypes (MST) of metastatic breast cancer (MBC). J. Clin. Oncol. 28(Suppl. 15), 1094 (2010).
21. Dee JF, Endacott R. Doing the right thing at the right time. J. Nurs. Manag. 19(2), 186-192 (2011).
22. Andersson Y, Frisell J, Sylvan M de Boniface J Bergkvist L. Breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes. Journal Clinical Oncology. 28(17), 2868-2873 (2010).
23. Lacovelli R, Lanoy E, Albiges L, Escudier B. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. BJU Int. 110(11), 1743-1753 (2012).
24. Fischer K, Kettunen J, Würtz P et al. Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: An observational study of 17,345 persons. PLoS Med. 11(2), e100160100166 (2014).